Alzheimer’s disease (AD): lecanemab treatment

Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .

Alzheimer’s disease (AD): lecanemab treatment. This is a monoclonal antibody. It is indicated in early AD. Fully referenced neurology checklist.

General

  • This is a monoclonal antibody
  • It is indicated in early AD
  • It moderately improves cognition, function and behaviour
  • It reduces markers of amyloid

Eligibility

Locked: subscribe to see this section.

Administration

Locked: subscribe to see this section.

Adverse effects

Locked: subscribe to see this section.

Stopping indications

Locked: subscribe to see this section.

References

  1. Mummery CJ, Rasmussen J, Blackburn D, et al. Lecanemab appropriate use recommendations for clinical practice in the UK. JNNP 2026; 97:372-384.
  2. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med 2023; 388:9-21.
  3. Qiao Y, Chi Y, Zhang Q, Ma Y. Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. Front Aging Neurosci 2023; 15:1169499.
  4. Schwartz NU, Dietz CD, Prufer Araújo I, et al. Changes of a cerebral cavernous malformation associated with lecanemab therapy in a patient with Alzheimer disease. Neurol Clin Pract 2025; 15:e200508.
  5. Paczynski M, Hofmann A, Posey Z, et al. Lecanemab treatment in a specialty memory clinic. JAMA Neurol 2025; 82:655-665.

Related checklists

Loading...